1.03

0.96% -0.01

After Hours: 1.03

Lucid Diagnostics Inc (LUCD)

Overview News Price History Financials Discussions Forecast

Lucid Diagnostics Inc stock is currently priced at $1.03, with a 24-hour trading volume of 418.21K. It has seen a -0.96% decreased in the last 24 hours and a +11.03% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.02 pivot point. If it approaches the $1.09 resistance level, significant changes may occur.

Previous Close:

$1.04

Open:

$1.06

24h Volume:

418.21K

Market Cap:

$51.28M

Revenue:

$2.43M

Net Income/Loss:

$-52.67M

P/E Ratio:

-0.7055

EPS:

-1.46

Net Cash Flow:

$-33.04M

1W Performance:

+14.32%

1M Performance:

+11.03%

6M Performance:

-20.16%

1Y Performance:

-31.33%

1D Range:

$1.0101

$1.11

52W Range:

$0.6301

$1.85

Lucid Diagnostics Inc Stock (LUCD) Company Profile

Name

Lucid Diagnostics Inc

Sector

Healthcare (1216)

Industry

Medical Devices (160)

Phone

212 949 4319

Address

One Grand Central Place, Suite 4600, New York

Employee

Twitter

Next Earnings Date

2024-03-26

Latest SEC Filings

LUCD's Discussions on Twitter

Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-27-21	Initiated	Ascendiant Capital Markets	Buy
Nov-08-21	Initiated	BTIG Research	Buy
Nov-08-21	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Needham	Buy

Lucid Diagnostics Inc Stock (LUCD) Financials Data

Lucid Diagnostics Inc (LUCD) Revenue 2024

LUCD reported a revenue (TTM) of $2.43 million for the quarter ending December 31, 2023.

Lucid Diagnostics Inc (LUCD) Net Income 2024

LUCD net income (TTM) was -$52.67 million for the quarter ending December 31, 2023, a +6.24% increase year-over-year.

Lucid Diagnostics Inc (LUCD) Cash Flow 2024

LUCD recorded a free cash flow (TTM) of -$33.04 million for the quarter ending December 31, 2023, a -7.99% decrease year-over-year.

Lucid Diagnostics Inc (LUCD) Earnings per Share 2024

LUCD earnings per share (TTM) was -$1.26 for the quarter ending December 31, 2023, a +18.71% growth year-over-year.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.